Brokers Set Expectations for Shattuck Labs FY2024 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) - Research analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Shattuck Labs in a research report issued to clients and investors on Monday, March 17th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings per share of ($1.42) for the year. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Shattuck Labs' current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs' Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Leerink Partners started coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an "outperform" rating and a $4.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.50.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK traded up $0.04 during trading on Thursday, hitting $1.24. 57,297 shares of the company's stock were exchanged, compared to its average volume of 378,817. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76. The company has a market cap of $59.20 million, a price-to-earnings ratio of -0.81 and a beta of 1.66. The business's 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.53.

Remove Ads

Institutional Trading of Shattuck Labs

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Shattuck Labs by 0.9% during the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company's stock worth $3,184,000 after acquiring an additional 8,133 shares during the last quarter. Atom Investors LP purchased a new position in Shattuck Labs in the 3rd quarter worth about $35,000. JPMorgan Chase & Co. raised its stake in shares of Shattuck Labs by 63.2% during the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company's stock valued at $96,000 after acquiring an additional 10,667 shares in the last quarter. Readystate Asset Management LP purchased a new position in Shattuck Labs during the 3rd quarter worth $39,000. Finally, MetLife Investment Management LLC lifted its holdings in shares of Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company's stock worth $86,000 after buying an additional 13,859 shares during the period. 58.74% of the stock is currently owned by institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.